AFATINIB FOR CHORDOMA: A phase II, single arm, multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in metastatic or unresectable chordoma

ChonDRAgon :A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX109 in Unresectable or Metastatic Conventional Chondrosarcoma

ESPRIT: ESP1/SARC025 Global Collaboration: A phase I study of a combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in patients with previously treated, incurable Ewing sarcoma

FaR-RMS: An overarching study for children and adults with frontline and relapsed rhabdomyosarcoma

GSK 7011618 SCOOP :Phase I Niraparib and Dostarlimab in paediatric patients with recurrent or refractory solid tumours

ICONIC: Improving outcomes through collaboration in osteosarcoma

J1S-MC-JV02: Protocol Addendum J1S-MC-JV02(a) A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma

Kindred Study: The international sarcoma kindred study: a global multi-site prospective cancer genetics study

MOTION: A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)

PREDICT B: Predicting radiotherapy response, toxicities and quality of life related functional  outcome in soft tissue sarcoma of the extremities: a prospective observational cohort study

rEECUr: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

SMPaeds: Stratified medicine paediatrics: genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy

SPEARHEAD 1: A phase II single arm open-label clinical trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

SSG XXII: A phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with the tyrosine kinase inhibitor Imastinib Mesylate of operable gastrointestinal stromal cells tumour (GIST) with a high risk for recurrence

Sometimes there may be other trials open - it is always worth asking your doctor.